Dennis Burns, Sector Specialist – Healthcare

 Dennis Burns is a Sector Specialist in the Healthcare practice at Daybreak Capital Partners.  Mr. Burns is also a Principal at TCG, a business development and interim management consulting firm specializing in medical devices, diagnostics and biotechnology.

 Mr. Burns has 30 years of management, market development, R&D and licensing experience in large and small medical device, pharmaceutical, biologicals and consumer firms including Johnson & Johnson, where he rose to Vice President, Licensing and International Development at Ortho Biotech.  In addition, Mr. Burns was Vice President/General Manager of the Internal Adhesives Division of Closure Corporation (acquired by Ethicon / J&J), an advisor to Westaim in Canada, creating the US launch strategy for ACTICOAT® (acquired by Smith & Nephew).

 Mr. Burns has also been CEO of two North Carolina venture-funded start-up biotech firms, one in immunology and one in asthma therapeutics, and has assisted a number of European medical device companies enter the US market.

Mr. Burns was educated at Manhattan College (BS, Biology) and the Yale University School of Medicine.